Brazil

Population 2018

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>95 (81–110)</td>
<td>45 (39–52)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>11 (9.3–13)</td>
<td>5.2 (4.4–6)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>2.5 (1.9–3.2)</td>
<td>1.2 (0.89–1.5)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.8 (4.6–5)</td>
<td>2.3 (2.2–2.4)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>1.9 (1.4–2.4)</td>
<td>0.88 (0.68–1.1)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases 1.5% (1.1–2)

Previously treated cases 8% (6–10)

TB case notifications, 2018

Total new and relapse 82 409

- % tested with rapid diagnostics at time of diagnosis 34%
- % with known HIV status 79%
- % pulmonary 87%
- % bacteriologically confirmedººº 74%
- % children aged 0–14 years 3%
- % women 29%
- % men 68%

Total cases notified 90 527

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 87% (75–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018 7% (6–8)

TB/HIV care in new and relapse TB patients, 2018

Number (%) Patients with known HIV status who are HIV-positive
- on antiretroviral therapy 7 445 11%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº

- New cases 43%
- Previously treated cases 48%

Laboratory-confirmed cases* MDR/RR-TB: 1 119, XDR-TB: 26

Patients started on treatment* ** MDR/RR-TB: 746, XDR-TB: 26

MDR/RR-TB cases tested for resistance to second-line drugs 141

Treatment success rate and cohort size

Success Cohort
New and relapse cases registered in 2017 71% 78 652
Previously treated cases, excluding relapse, registered in 2017 39% 7 350
HIV-positive TB cases registered in 2017 51% 7 617
MDR/RR-TB cases started on second-line treatment in 2016 61% 546
XDR-TB cases started on second-line treatment in 2016 41% 17

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 38

Funding source: 100% domestic, <1% international, 0% unfunded

*Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº MDR/RR-TB: 1 119, XDR-TB: 26
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-05
Data: www.who.int/tb/data